RBC reiterates Medicis at outperform

Medicis Pharmaceutical Corp. was reiterated by RBC Capital Markets analyst Ken Trbovich at outperform, above average risk with a $34 price target. IMS data indicates Solodyn prescriptions are up at 4,900 for the week ending Aug. 4. Solodyn prescriptions now support annualized sales of $92 million. Oral acne prescriptions continue on pace above the analyst's estimates. RBC believes peak potential for Solodyn is between $175 million and $250 million in annual gross sales. Shares of the Scottsdale, Ariz.-based pharmaceutical company were down 10 cents, or 0.35%, at $28.14, on volume of 853,900 shares versus the three-month running average of 1,166,820 shares. (NYSE: MRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.